scholarly journals Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Michiko Takakura ◽  
Akira Yokomizo ◽  
Yoshinori Tanaka ◽  
Michimoto Kobayashi ◽  
Giman Jung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Carbonic Anhydrase ◽  
Cancer Patients ◽  
Plasma Proteins ◽  
Specific Antigen ◽  
Healthy Controls ◽  
Gray Zone ◽  
Plasma Biomarker ◽  
Carbonic Anhydrase I ◽  
Discrimination Rate

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (, Mann-Whitney test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

scholarly journals A study of serum levels of prostate specific antigen, prostate acid phosphatase in prostate cancer patients and its complications on liver

2021 ◽  
Vol 8 (2) ◽  
pp. 554
Author(s):  
Balakrishna S. V. ◽  
Veerabhadra Goud G. K. ◽  
Veluri Ganesh
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Early Detection ◽  
Liver Function ◽  
Cancer Patients ◽  
Specific Antigen ◽  
Serum Levels ◽  
Liver Function Tests ◽  
Healthy Controls ◽  
Pathological Changes

Background: The prostate cancer (PC) is most leading disorders in human beings particularly in males. Prostate specific antigen (PSA) and prostate acid phosphatase (PAP) are tumor markers useful for early detection and diagnosis of PC. In prostate cancer patients more prone to liver and bone cancer metastasis because in these patients elevated levels of serum liver function tests (LFT) and these liver enzymes more specific for early detection of pathological changes in liver and bones.Methods: This is the case control study was carried out the association of serum levels of PSA/PAP inpatients with prostate cancer and healthy controls. Total 120 subjects included in this study in that 60 PC patients and 60 controls was included and blood was collected. The serum PSA levels are estimated by ELISA, PAP estimated by Kinetic method and LFT Was analyzed by commercial kits. Results: The present study evaluates the serum levels of LFT, PSA and PAP in patients with prostate cancer and compared with the healthy controls. The statistically significant difference between the PSA, PAP and LFT levels in patients with PC when compared to controls. The positive correlation in between PSA, PAP with LFT (p=0.001).Conclusions: This study suggesting that the serum PSA, PAP levels sensitive parameters for early detection of prostatic cancer and also for these patients’ frequent measurements of serum liver function tests, useful for early detection of significant pathological changes occurs in the liver and bone cancers metastasis from prostate.   

scholarly journals Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 ◽  
Author(s):  
Pei Chen ◽  
Yu-ling Zhang ◽  
Bai Xue ◽  
Guo-ying Xu
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Intraepithelial Neoplasia ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Feature ◽  
Caveolin 1 ◽  
The Relationship

PurposeThe prognostic value of caveolin-1 in prostate cancer remains uncertain. Hence, this meta-analysis was performed to evaluate the prognostic value of caveolin-1 in prostate cancer, as well as ascertain the relationship between caveolin-1 expression and clinicopathological characteristics of prostate cancer patients.MethodsThe PubMed, Embase, Chinese National Knowledge Infrastructure and Chinese Biology Medicine databases were electronically searched to retrieve published studies on caveolin-1 expression in prostate cancer. After study selection and data extraction, the meta-analysis was conducted using Review manager 5.3 software. Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. Funnel plot was used to assess publication bias.ResultsA total of ten studies were enrolled, which included 3976 cases of prostate cancer, 72 cases of high-grade intraepithelial neoplasia (HGPIN), and 157 normal controls. Results of the meta-analysis showed that the positive rate of caveolin-1 expression in prostate cancer was 18.28 times higher than that in normal control (OR= 18.28, 95% CI: 9.02–37.04, p<0.01), and 4.73 times higher than that in HGPIN (OR= 4.73, 95% CI: 2.38–9.42, p<0.01). The relationship between caveolin-1 and clinicopathological characteristics of prostate cancer showed that the differences in caveolin-1 expression in patients with prostate-specific antigen (PSA) >10 vs. ≤ 10 (OR=2.09, 95% CI: 1.35–3.22, p<0.01), differentiation degree low vs. medium/high (OR=2.74, 95% CI: 1.84–4.08, p<0.01), TNM stage T3+T4 vs. T1+T2 (OR=2.77, 95% CI: 1.78–4.29, p<0.01), and lymph node metastasis present vs. absent (OR=2.61, 95% CI: 1.84–3.69, p<0.01) were statistically significant. The correlation analysis between caveolin-1 and the survival time of patients with prostate cancer demonstrated that caveolin-1 was closely related to the prognosis of prostate cancer patients (HR=1.50, 95% CI: 1.28–1.76, p<0.01).ConclusionCaveolin-1 is overexpressed in prostate cancer, which can serve as a risk factor and adverse clinicopathological feature of prostate cancer. Caveolin-1 can also predict poor survival in prostate cancer patients after radical prostatectomy.

scholarly journals Plasma Lipidomic Profiles of Kidney, Breast, and Prostate Cancer Patients Differ from Healthy Controls

2021 ◽  
Author(s):  
Denise Wolrab ◽  
Robert Jirásko ◽  
Ondřej Peterka ◽  
Jakub Idkowiak ◽  
Michaela Chocholoušková ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Clinical Medicine ◽  
Tumor Stage ◽  
Blood Analysis ◽  
Blood Collection ◽  
Healthy Controls ◽  
Lipid Species ◽  
Breast And Prostate Cancer ◽  
Sensitivity Specificity

Abstract Early cancer screening is one of the unmet needs in clinical medicine. The peripheral blood analysis is a preferred method for efficient population screening as blood collection is well embedded in clinical practice and minimally invasive for patients. Lipids are important biomolecules, and variations in lipid concentrations may reflect pathological disorders. The lipidomic profiling by ultrahigh-performance supercritical fluid chromatography hyphenated to mass spectrometry of human plasma for distinguishing samples obtained from breast, kidney, and prostate cancer patients and healthy controls is investigated. The mean sensitivity, specificity, and accuracy of the new lipidomic profiling approach were 85%, 95%, and 92% for kidney cancer; 91%, 97%, and 94% for breast cancer; and 87%, 95%, and 92% for prostate cancer. No association of statistical models with tumor stage is observed. The statistically most significant lipid species for differentiation of studied cancer types are CE 16:0, Cer 42:1, LPC 18:2, PC 36:2, PC 36:3, SM 32:1, and SM 41:1.

Sign in / Sign up

Export Citation Format

Share Document